Drug Trial Radar · NCT07733856
Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Spruce BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Jul 29, 2026
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 12 months
Summary
As written by the sponsor on the registry.
This is an intermediate-size patient population Early Access Program (EAP) providing access to intracerebroventricular (ICV) tralesinidase alfa (TA) for participants with mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo Syndrome Type B). The primary objectives are to allow early access to TA treatment and to evaluate the safety and tolerability of TA ICV infusion. Approximately 10 participants will be enrolled at up to 3 US sites and treated with TA once weekly via ICV infusion for up to approximately 52 weeks, or until TA becomes commercially available.
Conditions
- Mucopolysaccharidosis Type IIIB
- MPS IIIB (Sanfilippo B Syndrome)
Interventions
Tralesinidase alfa (TA)Drug
Tralesinidase alfa (TA) is a sterile solution of recombinant human alpha-N-acetylglucosaminidase fused with insulin-like growth factor 2 (rhNAGLU-IGF2), formulated at 30 mg/mL for ICV infusion. Dose: 200 mg (6.7 mL) for participants age ≥12 to \<24 months; 300 mg (10 mL) for participants age ≥24 months. Administered once weekly via ICV reservoir following isovolumetric removal of up to 10 mL CSF, infused over approximately 10 minutes. Stored frozen at -40°C (±10°C).
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Hospital Oakland Research Institution
Oakland, California · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.